BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 8695820)

  • 1. Relapse after non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: early transplantation, use of an unrelated donor, and chronic graft-versus-host disease are protective.
    Enright H; Davies SM; DeFor T; Shu X; Weisdorf D; Miller W; Ramsay NK; Arthur D; Verfaillie C; Miller J; Kersey J; McGlave P
    Blood; 1996 Jul; 88(2):714-20. PubMed ID: 8695820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia.
    Hessner MJ; Endean DJ; Casper JT; Horowitz MM; Keever-Taylor CA; Roth M; Flomenberg N; Drobyski WR
    Blood; 1995 Nov; 86(10):3987-96. PubMed ID: 7579370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.
    Drobyski WR; Hessner MJ; Klein JP; Kabler-Babbitt C; Vesole DH; Margolis DA; Keever-Taylor CA
    Blood; 1999 Jul; 94(2):434-41. PubMed ID: 10397710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient.
    Spencer A; Szydlo RM; Brookes PA; Kaminski E; Rule S; van Rhee F; Ward KN; Hale G; Waldmann H; Hows JM; Batchelor JR; Goldman JM
    Blood; 1995 Nov; 86(9):3590-7. PubMed ID: 7579468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone marrow transplantation for chronic myelogenous leukemia: clinical outcomes.
    Enright H; Davies S; McGlave P
    Clin Transpl; 1994; ():283-93. PubMed ID: 7547549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia.
    Dazzi F; Szydlo RM; Cross NC; Craddock C; Kaeda J; Kanfer E; Cwynarski K; Olavarria E; Yong A; Apperley JF; Goldman JM
    Blood; 2000 Oct; 96(8):2712-6. PubMed ID: 11023502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of CML with unrelated donor marrow transplant.
    McGlave P
    Leuk Lymphoma; 1993; 11 Suppl 1():209-11. PubMed ID: 8251898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Related donor marrow transplant for chronic myeloid leukemia: patient characteristics predictive of outcome.
    Enright H; Daniels K; Arthur DC; Dusenbery KE; Kersey JH; Kim T; Miller WJ; Ramsay NK; Vercellotti GM; Weisdorf DJ; McGlave PB
    Bone Marrow Transplant; 1996 Apr; 17(4):537-42. PubMed ID: 8722351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program.
    McGlave P; Bartsch G; Anasetti C; Ash R; Beatty P; Gajewski J; Kernan NA
    Blood; 1993 Jan; 81(2):543-50. PubMed ID: 8422471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
    Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
    Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.
    Alyea EP; Soiffer RJ; Canning C; Neuberg D; Schlossman R; Pickett C; Collins H; Wang Y; Anderson KC; Ritz J
    Blood; 1998 May; 91(10):3671-80. PubMed ID: 9573003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
    Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E;
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors.
    Davies SM; DeFor TE; McGlave PB; Miller JS; Verfaillie CM; Wagner JE; Weisdorf DJ
    Am J Med; 2001 Apr; 110(5):339-46. PubMed ID: 11286947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Allogeneic bone marrow transplantation in chronic myeloid leukemia. The clinical results and risk factors in 70 patients].
    Tomás JF; Peñarrubia MJ; García JA; Figuera A; Gómez-García de Soria V; Steegmann JL; Arranz R; Cámara R; Gabriel R; Vázquez L
    Med Clin (Barc); 1995 Nov; 105(16):605-11. PubMed ID: 8523939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia.
    Drobyski WR; Ash RC; Casper JT; McAuliffe T; Horowitz MM; Lawton C; Keever C; Baxter-Lowe LA; Camitta B; Garbrecht F
    Blood; 1994 Apr; 83(7):1980-7. PubMed ID: 8142664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation.
    Giralt S; Hester J; Huh Y; Hirsch-Ginsberg C; Rondón G; Seong D; Lee M; Gajewski J; Van Besien K; Khouri I; Mehra R; Przepiorka D; Körbling M; Talpaz M; Kantarjian H; Fischer H; Deisseroth A; Champlin R
    Blood; 1995 Dec; 86(11):4337-43. PubMed ID: 7492795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society.
    Espérou H; Boiron JM; Cayuela JM; Blanchet O; Kuentz M; Jouet JP; Milpied N; Cahn JY; Faucher C; Bourhis JH; Michallet M; Tanguy ML; Vernant JP; Gabert J; Bordigoni P; Ifrah N; Baruchel A; Dombret H;
    Bone Marrow Transplant; 2003 May; 31(10):909-18. PubMed ID: 12748668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
    Millot F; Esperou H; Bordigoni P; Dalle JH; Michallet M; Michel G; Bourhis JL; Kuenz M; Blaise D; Garban F; Plouvier E; Rome A; Guilhot J; Guilhot F
    Bone Marrow Transplant; 2003 Nov; 32(10):993-9. PubMed ID: 14595387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unrelated donor marrow transplantation in children.
    Balduzzi A; Gooley T; Anasetti C; Sanders JE; Martin PJ; Petersdorf EW; Appelbaum FR; Buckner CD; Matthews D; Storb R; Sullivan KM; Hansen JA
    Blood; 1995 Oct; 86(8):3247-56. PubMed ID: 7579422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Unrelated Allogeneic Bone Marrow Transplantation Facilitated by the Japan Marrow Donor Program.
    Miyamoto T; Fukuda T; Nakashima M; Henzan T; Kusakabe S; Kobayashi N; Sugita J; Mori T; Kurokawa M; Mori SI
    Biol Blood Marrow Transplant; 2017 Jun; 23(6):938-944. PubMed ID: 28219836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.